- Home
- RLI vs LEGN Comparison
RLI vs LEGN Comparison
Compare RLI & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLI
- LEGN
- Stock Information
- Founded
- RLI 1965
- LEGN 2014
- Country
- RLI United States
- LEGN United States
- Employees
- RLI N/A
- LEGN N/A
- Industry
- RLI Property-Casualty Insurers
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- RLI Finance
- LEGN Health Care
- Exchange
- RLI Nasdaq
- LEGN Nasdaq
- Market Cap
- RLI 6.8B
- LEGN 7.0B
- IPO Year
- RLI 1985
- LEGN 2020
- Fundamental
- Price
- RLI $75.70
- LEGN $27.78
- Analyst Decision
- RLI Hold
- LEGN Strong Buy
- Analyst Count
- RLI 8
- LEGN 13
- Target Price
- RLI $78.60
- LEGN $75.67
- AVG Volume (30 Days)
- RLI 380.0K
- LEGN 1.5M
- Earning Date
- RLI 04-23-2025
- LEGN 05-13-2025
- Dividend Yield
- RLI 6.45%
- LEGN N/A
- EPS Growth
- RLI N/A
- LEGN N/A
- EPS
- RLI 3.03
- LEGN N/A
- Revenue
- RLI $1,733,218,000.00
- LEGN $728,303,000.00
- Revenue This Year
- RLI N/A
- LEGN $65.96
- Revenue Next Year
- RLI $5.96
- LEGN $52.55
- P/E Ratio
- RLI $24.69
- LEGN N/A
- Revenue Growth
- RLI 8.88
- LEGN 112.46
- 52 Week Low
- RLI $68.50
- LEGN $29.27
- 52 Week High
- RLI $91.15
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- RLI 52.52
- LEGN 29.61
- Support Level
- RLI $72.85
- LEGN $30.25
- Resistance Level
- RLI $75.14
- LEGN $33.30
- Average True Range (ATR)
- RLI 1.20
- LEGN 1.78
- MACD
- RLI 0.16
- LEGN -0.57
- Stochastic Oscillator
- RLI 95.13
- LEGN 5.19
About RLI RLI Corp. (DE)
RLI Corp underwrites property and casualty insurance through its subsidiaries. The company offers insurance coverage in the specialty admitted market, where the products are designed for special risks. It also offers products in the excess and surplus markets, which provides an alternative for customers with risks or loss exposures that generally cannot be written in the standard admitted market. RLI distributes property and casualty insurance through its wholly-owned branch offices that market to wholesale and retail producers. The company's insurance operation segments include Casualty, Property, and Surety and it derives a majority of its revenue from the Casualty segment.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.